Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1

Neuropsychopharmacology

Volumn 32, Issue 7, 2007, Pages 1531-1539

  Liu, Guo Xiang ^a,b   Cai, Guo Qiang ^a   Cai, You Qing ^a,b,c   Sheng, Zhe Jin ^a   Jiang, Jie ^a   Mei, Zhengtong ^a   Wang, Zhu Gang ^c,d   Guo, Lihe ^a   Fei, Jian ^a,c,d  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Shanghai Nan Fang Model Organism Research Center   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anxiety; Depression; GABA transporter 1; Knockout mouse

Indexed keywords

4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID CARRIER 1; AMITRIPTYLINE; BUSPIRONE; CORTICOSTERONE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; TIAGABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; GABAERGIC SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; LIGHT DARK CYCLE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; CORTICOSTERONE; DEPRESSIVE DISORDER; DRUG RESISTANCE; FEMALE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPSYCHOLOGICAL TESTS; SEROTONIN; STRESS, PSYCHOLOGICAL;

EID: 34250340915     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301281     Document Type: Article

References (52)

1. Atack JR (2005). The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Invest Drugs 14: 601-618.
2. Banfi S, Cornelli U, Fonio W, Dorigotti L (1982). A screening method for substances potentially active on learning and memory. J Pharmacol Methods 8: 255-263.
3. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A (2002). Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 22: 10046-10052.
4. Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990). Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology (Berl) 101: 511-518.
5. Borden LA (1996). GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 29: 335-356.
6. Borsini F (1995). Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19: 377-395.
7. Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A (1988). On the role of endogenous GABA in the forced swimming test in rats. Pharmacol Biochem Behav 29: 275-279.
8. Cai YQ, Cai GQ, Liu GX, Cai Q, Shi JH, Shi J et al (2006). Mice with genetically altered GABA transporter subtype I (GAT1) expression show altered behavioral responses to ethanol. J Neurosci Res 84: 255-267.
9. Chiu CS, Brickley S, Jensen K, Southwell A, McKinney S, Cull-Candy S et al (2005). GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci 25: 3234-3245.
10. Chiu CS, Jensen K, Sokolova I, Wang D, Li M, Deshpande P et al (2002). Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. J Neurosci 22: 10251-10266.
11. Crane D (2003). Tiagabine for the treatment of anxiety. Depress Anxiety 18: 51-52.
12. Crawley JN (1981). Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15: 695-699.
13. Crawley JN (1999). Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835: 18-26.
14. Ferguson GD, Herschman HR, Storm DR (2004). Reduced anxiety and depression-like behavior in synaptotagmin IV (-/-) mice. Neuropharmacology 47: 604-611.
15. File SE (2001). Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 125: 151-157.
16. Frazer A (1997). Antidepressants. J Clin Psychiatry 58(Suppl 6): 9-25.
17. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1999). Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93: 1251-1262.
18. Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel MC et al (1990). Cloning and expression of a rat brain GABA transporter. Science 249: 1303-1306.
19. Hascoet M, Bourin M, Dhonnchadha BA (2001). The mouse light-dark paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry 25: 141-166.
20. Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L et al (2003a). Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plusmaze. Neuropsychopharmacology 28: 1031-1044.
21. Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL (2003b). Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28: 2077-2088.
22. Holmes A, Yang RJ, Murphy DL, Crawley JN (2002). Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27: 914-923.
23. Jensen K, Chiu CS, Sokolova I, Lester HA, Mody I (2003). GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus. J Neurophysiol 90: 2690-2701.
24. Johnston GA (1996). GABAA receptor pharmacology. Pharmacol Ther 69: 173-198.
25. Kalueff A, Nutt DJ (1996). Role of GABA in memory and anxiety. Depress Anxiety 4: 100-110.
26. Katsurabayashi S, Kubota H, Tokutomi N, Akaike N (2003). A distinct distribution of functional presynaptic 5-HT receptor subtypes on GABAergic nerve terminals projecting to single hippocampal CA1 pyramidal neurons. Neuropharmacology 44: 1022-1030.
27. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G et al (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl 1): S71-S80.
28. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin) 92: 180-185.
29. Lydiard RB (2003). The role of GABA in anxiety disorders. J Clin Psychiatry 64(Suppl 3): 21-27.
30. Mathis C, Paul SM, Crawley JN (1994). Characterization of benzodiazepine-sensitive behaviors in the A/J and C57BL/6J inbred strains of mice. Behav Genet 24: 171-180.
31. Mikkelsen JD, Soderman A, Kiss A, Mirza N (2005). Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis. Eur J Pharmacol 519: 223-230.
32. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C (1991). Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196: 257-266.
33. Porsolt RD (2000). Animal models of depression: utility for transgenic research. Rev Neurosci 11: 53-58.
34. Porsolt RD, Bertin A, Jalfre M (1977a). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
35. Porsolt RD, Le Pichon M, Jalfre M (1977b). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
36. Radian R, Ottersen OP, Storm-Mathisen J, Castel M, Kanner BI (1990). Immunocytochemical localization of the GABA transporter in rat brain. J Neurosci 10: 1319-1330.
37. Rekling JC, Jahnsen H, Mosfeldt Laursen A (1990). The effect of two lipophilic gamma-aminobutyric acid uptake blockers in CA1 of the rat hippocampal slice. Br J Pharmacol 99: 103-106.
38. Sayin U, Purali N, Ozkan T, Altug T, Buyukdevrim S (1992). Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol Biochem Behav 43: 529-535.
39. Schaller JL, Thomas J, Rawlings D (2004). Low-dose tiagabine effectiveness in anxiety disorders. Med Gen Med 6: 8.
40. Schmitt U, Hiemke C (1999). Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plusmaze. Behav Pharmacol 10: 131-137.
41. Seckl JR, Campbell JC, Edwards CR, Christie JE, Whalley LJ, Goodwin GM et al (1990). Diurnal variation of plasma corticosterone in depression. Psychoneuroendocrinology 15: 485-488.
42. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994). Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology (Berlin) 116: 56-64.
43. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
44. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M et al (1987). The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11: 659-671.
45. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berlin) 85: 367-370.
46. Strickland PL, Deakin JF, Percival C, Dixon J, Gater RA, Goldberg DP (2002). Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry 180: 168-173.
47. Takahashi LK, Kalin NH, Vanden Burgt JA, Sherman JE (1989). Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci 103: 648-654.
48. Tao R, Auerbach SB (2000). Regulation of serotonin release by GABA and excitatory amino acids. J Psychopharmacol 14: 100-113.
49. Tsang SY, Xue H (2004). Development of effective therapeutics targeting the GABAA receptor: naturally occurring alternatives. Curr Pharm Des 10: 1035-1044.
50. Urani A, Chourbaji S, Gass P (2005). Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci Biobehav Rev 29: 805-828.
51. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R et al (1999). Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 45: 1070-1074.
52. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H (1993). Ketoconazole administration in hyper-cortisolemic depression. Am J Psychiatry 150: 810-812.